Literature DB >> 9462661

Hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda patients: the influence of virus C infection.

M J Moran1, A Fontanellas, E Brudieux, I Hombrados, V de Ledinghen, P Couzigou, H de Verneuil, R E De Salamanca.   

Abstract

Porphyria cutanea tarda (PCT) is caused by a decreased activity of the hepatic enzyme uroporphyrinogen decarboxylase (URO-D). This deficiency causes overproduction, hepatic deposition, and increased excretion of uroporphyrin. Iron overload and hepatic viral infections are considered aggravating factors of the disease. Two forms of PCT have been described, as follows: a familial one with an inherited decrease of URO-D activity in all tissues and a sporadic one with a decreased activity of URO-D restricted to the liver. To assess whether the hepatic URO-D returns to normal during a remission of the disease, this activity was measured in liver biopsy samples in 24 sporadic PCT patients. The hepatic and urinary porphyrin concentrations were also measured. Viral status and histopathological findings were analyzed to assess their involvement in PCT. Six patients treated by phlebotomy to reduce hepatic iron and who were considered to be in clinical remission, characterized by a disappearance of cutaneous lesions, showed higher hepatic URO-D activities and lower hepatic porphyrin concentrations than did patients with overt PCT. The medians of these variables, however, did not achieve normal values. The hepatic URO-D activity showed a significant inverse relationship with both hepatic porphyrins and urinary uroporphyrin excretion. Hepatic URO-D activity was not reduced by hepatitis C virus (HCV) infection and liver damage. We conclude that the achievement of remission in PCT largely depends on the transient normalization of hepatic URO-D activity. A small increase in hepatic coproporphyrin in nonporphyric patients could reflect hepatic injury/iron/alcohol-induced oxidative stress oxidizing the accumulated heme precursors rather than a direct effect on hepatic URO-D enzyme.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9462661     DOI: 10.1002/hep.510270237

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  9 in total

1.  Pancreatic involvement in chronic viral hepatitis.

Authors:  Yoshiki Katakura; Hiroshi Yotsuyanagi; Kiyoe Hashizume; Chiaki Okuse; Noriaki Okuse; Kohji Nishikawa; Michihiro Suzuki; Shiro Iino; Fumio Itoh
Journal:  World J Gastroenterol       Date:  2005-06-21       Impact factor: 5.742

Review 2.  Heme biosynthesis and the porphyrias.

Authors:  John D Phillips
Journal:  Mol Genet Metab       Date:  2019-04-22       Impact factor: 4.797

Review 3.  Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias.

Authors:  Vaithamanithi-Mudumbai Sadagopa Ramanujam; Karl Elmo Anderson
Journal:  Curr Protoc Hum Genet       Date:  2015-07-01

Review 4.  Role of HFE gene mutations in liver diseases other than hereditary hemochromatosis.

Authors:  H L Bonkovsky; J V Obando
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

5.  Liver cirrhosis induced by porphyria cutanea tarda: a case report and review.

Authors:  Kwang Gyun Lee; Jong Jin Hyun; Yeon Seok Seo; Bora Keum; Hyung Joon Yim; Yoon Tae Jeen; Hong Sik Lee; Hoon Jai Chun; Chang Duck Kim; Ho Sang Ryu; Soon Ho Um
Journal:  Gut Liver       Date:  2010-12-17       Impact factor: 4.519

6.  Autoantibodies to human cytosol: a marker of sporadic porphyria cutanea tarda.

Authors:  Y Ma; A L Fracanzani; M Sampietro; M Mattioli; P Cheeseman; R Williams; G Mieli-Vergani; D Vergani; S Fargion
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

7.  Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency.

Authors:  Norman G Egger; Douglas E Goeger; Deborah A Payne; Emil P Miskovsky; Steven A Weinman; Karl E Anderson
Journal:  Dig Dis Sci       Date:  2002-02       Impact factor: 3.199

Review 8.  Hepatitis C, porphyria cutanea tarda and liver iron: an update.

Authors:  F Ryan Caballes; Hossein Sendi; Herbert L Bonkovsky
Journal:  Liver Int       Date:  2012-04-17       Impact factor: 5.828

9.  PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3.

Authors:  Takashi Yoshikado; Kota Toshimoto; Kazuya Maeda; Hiroyuki Kusuhara; Emi Kimoto; A David Rodrigues; Koji Chiba; Yuichi Sugiyama
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-09-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.